Since the first child was born after *In Vitro* Fertilisation (IVF) in 1978, several studies have been conducted on the possible consequences of Assisted Reproductive Technologies (ART), which include standard IVF, Gamete Intra-Fallopian Transfer (GIFT) and Intra-Cytoplasmatic Sperm Injection (ICSI). Most papers on the consequences of ART concentrated on short-term outcomes, such as perinatal mortality, multiple pregnancies, weight at birth and malformations (reviewed in [Schieve *et al*, 2004](#bib30){ref-type="other"} and [Hansen *et al*, 2005](#bib16){ref-type="other"}), while few studies have considered the long-term effects of these techniques.

Now that several children born after ART have reached adolescence, it is useful to study the possible long-term consequences of this procedure, such as cancer incidence. Cases of cancer in children born after ART have been reported ([White *et al*, 1990](#bib35){ref-type="other"}; [Toren *et al*, 1995](#bib34){ref-type="other"}; [Rizk *et al*, 2000](#bib28){ref-type="other"}; [Cruysberg *et al*, 2002](#bib9){ref-type="other"}; [Lee *et al*, 2004](#bib18){ref-type="other"}); the hypotheses behind a possible association between ART and cancer could be the repeated hormonal exposure and/or the epigenetic modification of gene expression that may be activated by the manipulation of the gametes in the laboratory; however, the studies on this topic are scarce ([De Rycke *et al*, 2002](#bib10){ref-type="other"}; [Thompson *et al*, 2002](#bib33){ref-type="other"}; [Ayhan *et al*, 2004](#bib1){ref-type="other"}; [Brinton *et al*, 2004](#bib7){ref-type="other"}).

We review here the cohort studies that have considered the association between ART and cancer in children, and performed a meta-analysis of the available data.

MATERIALS AND METHODS
=====================

Published guidelines for meta-analysis of observational studies ([Stroup *et al*, 2000](#bib32){ref-type="other"}) were followed to perform the literature search and the analysis, and to report the results. Studies included in the present analysis had to meet the following inclusion criteria: they had to be cohort studies involving children born after ART (which represents the exposure of interest), and cancer (all types) had to be the end point. A search on Medline and Embase was performed for articles reported up to February 2005, using combinations of the keywords 'IVF\', 'ART\', 'children\', 'cohort\' and 'cancer\', and restricting the search to articles published in English.

A broad search yielded more than 2500 potentially relevant titles. The titles and the abstracts of the papers were screened independently by two experts, and 161 articles which contained information on both short- and long-term health outcomes of children born after ART were selected. Citation indices, bibliographies of the articles and review papers ([Brinton *et al*, 2004](#bib7){ref-type="other"}; [Schieve *et al*, 2004](#bib30){ref-type="other"}; [Lightfoot *et al*, 2005](#bib21){ref-type="other"}) were also checked to complete the search. We selected a total of 14 studies that met the inclusion criteria for the meta-analysis. A description of the studies is reported in [Table 1](#tbl1){ref-type="table"}.

Out of the 14 studies, five ([Bergh *et al*, 1999](#bib3){ref-type="other"}; [Ericson *et al*, 2002](#bib14){ref-type="other"}; [Pinborg *et al*, 2003](#bib27){ref-type="other"}, [2004a](#bib25){ref-type="other"}, [2004b](#bib26){ref-type="other"}) were partially overlapping, therefore only the two most recent publications, with the larger cohort were included in the meta-analysis ([Pinborg *et al*, 2004b](#bib26){ref-type="other"} for the Danish data set, [Ericson *et al*, 2002](#bib14){ref-type="other"} for the Swedish data set). The meta-analysis was therefore performed on 11 of the 14 data sets ([Table 2](#tbl2){ref-type="table"}), which reported pertinent, nonoverlapping, and comparable data. Three studies have different designs ([White *et al*, 1990](#bib35){ref-type="other"}; [Odone-Filho *et al*, 2002](#bib24){ref-type="other"}; [Moll *et al*, 2003](#bib22){ref-type="other"}), but were included since it was possible to calculate cancer incidence ratios from the available published data; however, a sensitive analysis was conducted by including and excluding these studies.

Statistical analysis
--------------------

Two studies ([Rufat *et al*, 1994](#bib29){ref-type="other"}; [Pinborg *et al*, 2004b](#bib26){ref-type="other"}) did not provide cancer incidence rates in a reference population. For the French study ([Rufat *et al*, 1994](#bib29){ref-type="other"}), the expected cases were extracted from the literature ([Bernard *et al*, 1993](#bib4){ref-type="other"}; [Gembara *et al*, 1995](#bib15){ref-type="other"}). Since the average period of follow-up of children born after ART was not reported in the original paper by Rufat, we estimated an average follow-up of 2.2 years, which is the mean between the minimum and the maximum period of follow-up.

For the Danish data sets ([Pinborg *et al*, 2003](#bib27){ref-type="other"}, [2004a](#bib25){ref-type="other"}, [2004b](#bib26){ref-type="other"}) the expected number of cases was calculated by applying the cancer incidence rate provided by the Danish Cancer Registry for children 0--6 years and for the period 1995--1999. The average period of follow-up used to calculate the number of expected cases was 4.1 years, as reported in a subsequent publication on the same cohort of children ([Lidegaard *et al*, 2005](#bib20){ref-type="other"}).

For the meta-analysis, the observed and expected cases from each study were added and the overall Standardised Incidence Ratio (SIR) was calculated as the ratio between the number of observed and the number of expected cases. The details for the calculation of the expected number of cases are reported for each study in [Table 2](#tbl2){ref-type="table"}. The exact confidence interval for SIR was obtained by using the Poisson\'s distribution.

The heterogeneity across studies was analysed with the Cochran\'s test. A SIR adjusted for study was then calculated, using either a fixed or a random-effects model, according to the results of the Cochran\'s test ([Normand, 1999](#bib23){ref-type="other"}).

The potential for publication bias was examined by drawing a 'funnel plot\' in which study-specific log effect estimates were plotted against their s.e. ([Sterne *et al*, 2000](#bib31){ref-type="other"}). Egger\'s test was performed to assess the symmetry of the funnel plot ([Begg and Mazumdar, 1994](#bib2){ref-type="other"}; [Egger *et al*, 1997](#bib12){ref-type="other"}). A significant asymmetry indicates the presence of bias, which was set in this analysis at a *P*-value \<0.05. The statistical analysis was performed using STATA package, version 8.

RESULTS
=======

Out of the 11 studies included in this meta-analysis, two were conducted in Australia, six in Europe, one in Israel, one in USA and one in Brasil. Eight were cohort studies, three ([White *et al*, 1990](#bib35){ref-type="other"}; [Odone-Filho *et al*, 2002](#bib24){ref-type="other"}; [Moll *et al*, 2003](#bib22){ref-type="other"}) the last two based on a hypothetical cohort and one based on national statistical data without a systematic follow-up of all the children in the cohort ([White *et al*, 1990](#bib35){ref-type="other"}).The follow-up varied from about 1 to 13 years ([Table 1](#tbl1){ref-type="table"}). None of the cohort studies reported a significant association between ART and childhood cancer. The three studies with a different design reported a significant increase of neuroectodermal cancer ([White *et al*, 1990](#bib35){ref-type="other"}), retinoblastoma ([Moll *et al*, 2003](#bib22){ref-type="other"}) or cancer in general ([Odone-Filho *et al*, 2002](#bib24){ref-type="other"}) in children conceived after IVF. The SIR for each study are presented in [Figure 1](#fig1){ref-type="fig"}.

The overall assumption of homogeneity between study-specific SIRs was rejected (*P*-value for Cochran\'s test \<0.001), even when restricted to the eight studies with similar design (*P*-value for Cochran\'s test: 0.003). The lack of homogeneity seemed to be due to two studies ([Lerner-Geva *et al*, 2000](#bib19){ref-type="other"}; [Bradbury and Jick, 2004](#bib6){ref-type="other"}), since the SIR=0 could strongly influence the result even though the studies included a small number of subjects (332 and 176, respectively). When these two studies were excluded from the analysis, the hypothesis of homogeneity could be accepted (*P*-value for Cochran\'s test: 0.76).

The final cohort included 38 815 subjects, with 38.21 cases of cancer expected *vs* 47 observed, giving a SIR of 1.23 (95% CI 0.93--1.37). The analysis restricted to eight studies (excluding the studies by White, Odone-Filho and Moll, with different designs) indicates 36.22 expected cases of childhood cancer and 35 observed, giving a SIR of 0.97 (95% CI 0.69--1.10).

The study-adjusted SIR was 1.33 (95% CI 0.62--2.85) when all the 11 studies were included, while it was 0.77 (95% CI 0.41--1.42) when the analysis was restricted to eight studies.

The overall analysis did not show publication bias (Egger\'s test *P*-value: 0.70), while there was evidence of publication bias for the restricted analysis (eight studies, Egger\'s test *P*-value: 0.02). When the two studies with SIR=0 were excluded, no evidence of publication bias was observed (*P*-value for the Egger\'s test: 0.40).

DISCUSSION
==========

Studies on childhood cancer in children born after ART have been conducted only recently, and are analysed in this paper. Overall, no increased risk of childhood cancer was found in the present analysis. A previous review on four of the studies included in this meta-analysis ([Lightfoot *et al*, 2005](#bib21){ref-type="other"}) provided a meta-SIR of 1.03 (95% CI 0.61--1.63).

Meta-analysis is a useful approach when studying rare diseases, such as childhood cancer, because the pooled data set has greater power than each individual study ([Egger and Smith, 1997](#bib13){ref-type="other"}; [Blettner *et al*, 1999](#bib5){ref-type="other"}). However, pooling data can also have certain limitations, ([Blettner *et al*, 1999](#bib5){ref-type="other"}; [Stroup *et al*, 2000](#bib32){ref-type="other"}), such as publication bias. Although our analysis suggests overall a lack of such bias, the number of studies included was small, and therefore our results are not conclusive.

Another issue is that the studies in a meta-analysis may differ considerably in quality, design, methods of data collection, definition of the exposure and type of confounding variables. To promote homogeneity, we included only cohort studies of children followed up for several years. Three studies ([White *et al*, 1990](#bib35){ref-type="other"}; [Odone-Filho *et al*, 2002](#bib24){ref-type="other"}; [Moll *et al*, 2003](#bib22){ref-type="other"}) presented a slightly modified design, so we performed a sensitivity analysis by including and excluding these studies from the metaestimates.

Our meta-analysis could not take into account the length of follow-up as a covariate, since not all the studies included specified it, and when they did, it appeared obvious that the follow-up period was different from study to study.

In this analysis, we concentrated on ART and did not consider studies of the possible negative consequences of hormones administered to the mothers for infertility problems, some of which have included suggestions of (nonsignificant) increases of childhood cancer. Similarly, studies of congenital malformation in relation to ART have not fallen within the scope of our meta-analysis.

In conclusion, this meta-analysis does not suggest an association between ART and childhood cancer, even though the limited number of studies prevent a firm conclusion and a pooled analysis would be useful.
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###### 

Cohort studies on *in vitro* fertilization and childhood cancer

  **Authors (year)**                                       **Country**      **Number of exposed children**     **Follow**-**up**                      **Cancer results**
  -------------------------------------------------------- ------------- ------------------------------------- -------------------------------------- -----------------------------------------------------------------------------------------
  [White *et al* (1990)](#bib35){ref-type="other"}         Australia                    2285^a^                Absent                                 Three neuroectodermal tumours
  [Rufat *et al* (1994)](#bib29){ref-type="other"}         France                        1637                  Minimum follow-up: 1 year              One leukaemia
  [Doyle *et al* (1998)](#bib11){ref-type="other"}         Britain                       2507                  Average follow-up: 8.6 years           Two unspecified cancers
  [Bergh *et al* (1999)](#bib3){ref-type="other"}          Sweden                        5586                  Maximum follow-up: 13 years            One ALL, one reticulosis, one upper extremities, one peripheral nerves cancer
  [Bruinsma *et al* (2000)](#bib8){ref-type="other"}       Australia                     5249                  Average follow-up: 3 years, 9 months   One brain, one connective tissue, three leukaemia, one salivary gland cancer
  [Lerner-Geva *et al* (2000)](#bib19){ref-type="other"}   Israel                         332                  710 person years                       0 cancers
  [Klip *et al* (2001)](#bib17){ref-type="other"}          Netherlands    9479 (429 after hormonal treatment)  Average follow-up: 4.6 years           Three leukemia, four unspecified cancers
  [Ericson *et al* (2002)](#bib14){ref-type="other"}       Sweden                        9056                  Maximum follow-up: 13 years            Three ALL, two histiocytosis, two sarcomas, two CNS, one retinal, one hepatic carcinoma
  [Odone-Filho *et al* (2002)](#bib24){ref-type="other"}   Brazil                         ^b^                  Maximum follow-up: 5 years             One AML, one neuroblastoma, two rhabdo myosarcoma
  [Moll *et al* (2003)](#bib22){ref-type="other"}          Netherlands                    ^c^                  Maximum follow-up: 1 year, 2 months    Five retinoblastoma
  [Pinborg *et al* (2003)](#bib27){ref-type="other"}       Denmark                 1080 (454 twins)            Maximum follow-up: 4 years             One 1 ALL, one germinal cell tumour
  [Pinborg *et al* (2004a)](#bib25){ref-type="other"}      Denmark                   3393 (twins)              Minimum follow-up: 1 year              0 cancers
  [Pinborg *et al* (2004b)](#bib26){ref-type="other"}      Denmark                 8523 (3393 twins)           Minimum follow-up: 1 year              ALL, hepatoblastoma, unspecific tumours of thorax, heart, cerebrum
  [Bradbury and Jick (2004)](#bib6){ref-type="other"}      USA                            176                  Maximum follow-up: 13 years            0 cancers

Cohort without a systematic follow-up.

Hypothetical cohort, assuming that approximately 2000 children were conceived after IVF during the period 1996--2000.

Hypothetical cohort, assuming that 1--1.5% of children were conceived after IVF.

ALL=acute lymphoblastic leukaemia; CNS=central nervous system; AML=acute myelocytic leukaemia.

###### 

Cohort studies included in the meta-analysis

  **Author (year)**                                                                         **Number of exposed children**  **Calculation of expected cases (EC)**                                                                                                                                                                                      **Observed/expected cases (*N*)**   **Standardized incidence ratio (95%CI)**
  ---------------------------------------------------------------------------------------- -------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------- ------------------------------------------
  [White *et al* (1990)](#bib35){ref-type="other"}                                                       2285               No calculation in the original study. EC calculated by applying cancer incidence rates from the original study to the IVF cohort                                                                                                         3/0.13                           23.08 (8.38--67.31)
  [Rufat *et al* (1994)](#bib29){ref-type="other"}                                                       1637               No calculation in the original study. EC calculated by applying published cancer incidence rates ([Bernard *et al*, 1993](#bib4){ref-type="other"}; [Gembara *et al*, 1995](#bib15){ref-type="other"}) to the IVF cohort                  1/0.7                            1.43 (0.31--3.79)
  [Doyle *et al* (1998)](#bib11){ref-type="other"}                                                       2507               Application of cumulative national cancer rates, taking into account year of birth and length of follow-up                                                                                                                                2/3.5                            0.57 (0.07--2.06)
  [Bruinsma *et al* (2000)](#bib8){ref-type="other"}                                                     5249               Application of the Victorian cancer incidence rates, taking into account age and length of follow-up                                                                                                                                     6/4.33                            1.39 (0.62--3.09)
  [Lerner-Geva *et al* (2000)](#bib19){ref-type="other"}                                                 332                Application of specific national cancer incidence rates, taking into account age, gender and year of diagnosis                                                                                                                            0/1.7                              0 (0--2.18)^a^
  [Klip *et al* (2001)](#bib17){ref-type="other"}                                                      9050^b^              Application of cancer incidence rates from the Eindhoven and the Netherlands Cancer Registries, taking into account age, gender and calendar period                                                                                      6/6.78                            0.88 (0.41--1.98)
  [Ericson *et al* (2002)](#bib14){ref-type="other"}                                                     9056               Application of the Swedish Cancer Registry cancer incidence rates, taking into account year of birth, maternal age, parity and length of involuntary childlessness                                                                       11/12.5                            0.88 (0.5--1.13)
  [Odone-Filho *et al* (2002)](#bib24){ref-type="other"}                                             Around 2000            Application of annual incidence rate of cancer for children aged 0--4 years                                                                                                                                                              4/1.17                            3.42 (1.42--8.76)
  [Moll *et al* (2003)](#bib22){ref-type="other"}                                                     Not known             Application of the 1-year age-specific mortality rates from statistics in the Netherlands                                                                                                                                                5/0.69                            7.25 (3.19--17.03)
  [Pinborg *et al* (2004a](#bib25){ref-type="other"}, [2004b)](#bib26){ref-type="other"}                 8523               No calculation in the original study. EC calculated by applying the 0--6 years cancer incidence rates from the Danish Cancer Registry to the IVF cohort                                                                                   9/6.7                            1.34 (0.71--1.78)
  [Bradbury and Jick (2004)](#bib6){ref-type="other"}                                                    176                No calculation in the original study. EC were calculated by applying retinoblastoma incidence rates from the original study to the IVF cohort                                                                                            0/0.01                              0 (0--7.40)^a^

The upper confidence limit was calculated using 0.5 as observed number of cases.

In all, 429 children conceived after hormonal treatment, but not after ART, were excluded.
